CELU News and Press, Celularity Inc. From 08/29/23

2023-08-29 09:10:07 ET More on Celularity Celularity announces $3M registered direct offering, stock up 8% Seeking Alpha’s Quant Rating on Celularity Earnings data for Celularity For further details see: Celularity announces multi-year research col...

Celularity to provide research support for Regeneron's targeted, allogeneic, chimeric antigen receptor (CAR) T-cell therapy Agreement underscores Celularity's demonstrated expertise in cell therapy research FLORHAM PARK, N.J., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. ...

2023-07-27 10:37:00 ET Celularity ( NASDAQ: CELU ) on Thursday announced an ~$3M registered direct offering of class A shares and warrants. Shares +7.9% in morning trade. The firm inked a deal with a healthcare-focused institutional investor for the ...

FLORHAM PARK, N.J., July 27, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“ Celularity ”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that it has entered into a definitive agreement with a ...

FLORHAM PARK, N.J. and TAMPA, Fla., July 27, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, and Verséa Ophthalmics, LLC (“Verséa Ophthal...

FLORHAM PARK, N.J., July 18, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity,” “the Company”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that it will present data on its...

FLORHAM PARK, N.J., June 29, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that the Company will present data from a new product technology in developme...

Data published online in the journal Cytotherapy demonstrate that CRISPR-mediated tissue factor gene knockout (TFKO) in allogeneic stromal cells (ASCs) leads to significantly lower tissue factor (TF) expression, activity, and thrombotic effects, providing a feasible strategy potentially to improv...

2023-05-26 11:56:25 ET Summary Even with new management in place, it is unlikely that a company will regain market share or turn profitable after it has lost its way. Carolina Dybeck Happe joined General Electric Company in March 2020 at a time when revenue had been declining shar...

2023-05-23 08:17:51 ET Celularity ( NASDAQ: CELU ) has received a $45M purchase order for Celularity private label Halal-Certified biomaterial products from Jamjoom Medical Store. This marks the first purchase order received by Celularity under its recently announced expan...